Tweets
Fernandes et al. CPPD assoc increased nephrolithiasis. 8.06% vs 4.88%; p<0.0001. @RheumNow #ACR22 Abstr#1819 https://t.co/o8Afmcc429 https://t.co/3EoOXpqpGN
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
Mortality in patients with SpA
Abstract #0569 #ACR22 @RheumNow
✏️systematic review/meta-analysis of 19 studies
✋No increased mortality in patients with PsA compared to gen. pop.
🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
How do we know what PMR is all about?
Imaging has helped enormously, and every step of the way, imaging has got better and better. Specific findings which reveal the culpable pathology.
@drceowen #ACR22 @RheumNow https://t.co/4OOOk0F3jW
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
NSAIDs and CV risk in Inflammatory Arthritis
Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting.
https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
#ACR2022 L07: Telitacicept - anti-BlyS and APRIL in SLE
335 pts P3 52 wk study TEL 160 mg SQ q7d vs PBO
83% SRI4 response in TEL vs 38% PBO (p<0.001)
As early as w4, sustained to w52
Most common AEs: URIs, decr IgG/IgM, injxn site rxn, UTI
@RheumNow #ACRBest https://t.co/UpEwEaonDO
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Khanna et al Transdermal NaHCO₃ in gout flare. N=98. Response rate D7 95% vs 79% (p=0.01). Lower rescue med, 6% vs 20%. @RheumNow #ACR22 Abstr#1787 https://t.co/DWtlvjzBHw https://t.co/DOk993gCwz
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
Joy et al. Disease activity rather than steroid use increases risk of diabetes in RA in BeST study over 10 years. @RheumNow #ACR22 Abstr#1987 https://t.co/VT2eb3Q4m9 https://t.co/kquZ70o9bU
Richard Conway @RichardPAConway ( View Tweet )
3 years 8 months ago
L08 #ACR22 TIX/CIL (Evusheld) in Rheum Pts
157 pts, f/u 154 days
24 breakthrough COVID ifns (15%)
2 pts required hospitalization, rest had mild-mod symptoms
No SAEs (CVD)
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
